Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

October 28, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

July 13, 2026July 13, 2026

Why Do We Age? The Biology Of Ageing Explained

1
October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

2
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

3
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

4
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

5
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Here’s how COVID-19 vaccine BNT162b1 produces human antibody and helper T-cell responses

Hong Kong PhD Fellowship Scheme (HKPFS) 2021-2022

Pet bearded dragons droppings cause Salmonella outbreak: Question is are they safe?

Here’s how COVID-19 vaccine BNT162b1 produces human antibody and helper T-cell responses
  • BiotechToday
  • India
  • World

Here’s how COVID-19 vaccine BNT162b1 produces human antibody and helper T-cell responses

bioxone October 4, 2020October 4, 2020

Ayooshi Mitra, Amity University Kolkata

To avert the spread of the pandemic of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), a successful vaccine is needed. In an examination directed recently, safety, tolerability, and neutralizer reaction information from an on-going placebo-controlled treatment observer-blinded phase 1/2 coronavirus disease 2019 (COVID-19) vaccine trial BNT162b1, a lipid nanoparticle (LNP) nucleoside-modified messenger RNA (mRNA) encoding the SARS-CoV-2 spike protein1 receptor-binding domain (RBD) was accounted for. Here, antibody and T-cell responses following BNT162b1 vaccination in a second, non-randomized, Phase 1/2 open-label trial in healthy adults aged 18-55 years were presented. 

Two dosages of 1 to 50 μg of BNT162b1 brought strong CD4 + and CD8 + T-cell and antibody responses, with RBD-binding IgG concentrations clearly above those in the COVID-19 sample (HCS) panel. For the 43rd day of SARS-CoV-2 serum neutralizing, mean values were 0.7-fold (1 μg) to 3.5-fold (50 μg) of the HCS panel. Immune sera broadly neutralized pseudoviruses with various SARS-CoV-2 spike variants. Most participants had positive T cell immune responses with CD8 + RBD-specific and CD4 + T-cell development. The tough RBD-specific antibody, T-cell, and favourable cytokine reactions induced by the BNT162b1 mRNA vaccine suggest multiple advantageous mechanisms with the potential to defend against the COVID-19.

References: Sahin, U., Muik, A., Derhovanessian, E. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses. Nature (2020). https://doi.org/10.1038/s41586-020-2814-7 https://www.nature.com/articles/s41586-020-2814-7

Also read: Can high systemic inflammation biomarkers during puberty result in breast cancer?

  • Why Do We Age? The Biology Of Ageing Explained
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged Antibody CORONAVIRUS COVID-19 cytokine reactions mRNA mRNA vaccine pandemic receptor binding SARS-CoV-2 successful vaccine T-cell and B-cell T-cell response VACCINE

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • India
  • World

Pet bearded dragons droppings cause Salmonella outbreak: Question is are they safe?

bioxone October 4, 2020

Prama Ghosh, Amity University Kolkata 13 people from 8 states have been infected with the outbreak strain of Salmonella muenster linked to bearded dragons, as of 25th September, according to the latest information released from the Centers for Disease Control and Prevention (CDC).  Pet bearded dragons are likely the source of this outbreak as shown […]

Salmonella

Related Post

  • BiotechToday
  • World

When machine-learning takes over healthcare in studying respiratory behaviors

bioxone November 10, 2020November 10, 2020

-Camelia Bhattacharyya, Amity University Kolkata Dave Waters once said, “A baby learns to crawl, walk and then run. We are in the crawling stage when it comes to applying machine learning”. This professor or scientist and researcher also said, “Machine learning will automate jobs that most people thought could only be done by people”. The […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Scientists develop Novel Cholera Vaccine from Rice Grains

BioTech Today June 29, 2021June 28, 2021

Agrima Bhatt, Rajasthan University What is Cholera? Cholera is a diarrheal sickness caused by the toxigenic bacterium Vibrio cholerae infecting the intestine. Each year, an estimated 2.9 million cases and 95,000 deaths occur in the population worldwide. The World Health Organization estimates that 1.3 million to 4 million people are infected with cholera each year, […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Turbinmicin- A New Fighter

bioxone November 28, 2020November 28, 2020

Shrayana Ghosh, Amity University Kolkata A new antifungal compound, discovered by the scientists of the University of Wisconsin-Madison, Madison that can target the multidrug-resistant and potentially deadly strains of the fungal pathogen Candida auris without causing any toxic side effects in mice. The team discovered a new molecule detected in the microbiome of a sea squirt from […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

Why Do We Age? The Biology Of Ageing Explained

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy